AI and Global Health: New Directions Between Innovation and Governance | Mckinsey generative ai report pdf | Google introduction to generative ai | What is generative ai google | Turtles AI

The World Health Organization (WHO) and the World Economic Forum (WEF) are advancing the adoption of AI in global healthcare. This initiative aims to improve the efficiency, accessibility and equity of healthcare services. Companies such as Avant Technologies, BioXcel Therapeutics, Tevogen Bio, Amesite and Palantir are developing innovative AI-based solutions to address clinical and operational challenges. The adoption of AI in healthcare could significantly transform the market, influencing investments, regulations and care models.

Key points:

• The WHO has designated the Digital Ethics Centre at Delft University of Technology as a Collaborative Centre for AI Governance in Healthcare.
• The WEF highlights the importance of investment in infrastructure, equity and scientific evidence for the implementation of AI in healthcare.
• Avant Technologies and Ainnova are expanding the use of the Vision AI platform in Latin America for the early diagnosis of chronic diseases.
• Other companies, including BioXcel Therapeutics, Tevogen Bio, Amesite, and Palantir, are developing AI solutions to improve healthcare delivery and operational efficiency.

The World Health Organization (WHO) recently designated the Digital Ethics Centre at Delft University of Technology in the Netherlands as a Collaborating Center for AI Governance in Healthcare, recognizing the importance of an ethical and responsible approach to the adoption of advanced digital technologies. In parallel, the World Economic Forum (WEF) has emphasized the need for targeted investments in infrastructure, equity, and scientific evidence to ensure effective and inclusive implementation of AI in global healthcare. In this context, companies such as Avant Technologies and Ainnova are collaborating to expand the use of the Vision AI platform in Latin America, with pilot projects in Chile and the Dominican Republic aimed at improving the early diagnosis of chronic diseases through the analysis of retinal images and clinical data. Concurrently, BioXcel Therapeutics is conducting Phase 3 clinical trials to evaluate the efficacy of BXCL501 in the treatment of agitation associated with bipolar disorder and schizophrenia in the home setting, while Tevogen Bio is developing the PredicTcell platform to model immunologically active peptides. Amesite has launched NurseMagic™, an AI platform to support non-clinical healthcare workers, and Palantir, in collaboration with R1 RCM, has created the R37 lab to optimize healthcare financial management through process automation. These developments signal the growing integration of AI in healthcare, with significant implications for operational efficiency, quality of care, and accessibility of healthcare services globally.

The adoption of AI in healthcare represents a significant evolution, with potential benefits for patients, providers, and healthcare systems as a whole.